
Liminatus Pharma (LIMN)
NasdaqMarket Closed
Liminatus Pharma, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, with a development pipeline aimed at cancers that remain difficult to treat with existing therapies. Its Class A common stock gives investors exposure to an early-stage drug developer whose value is tied primarily to clinical progress, regulatory outcomes, financing capacity, and the commercial potential of its experimental medicines.
The company’s lead disclosed programme is a Guanylyl Cyclase C, or GCC, vaccine being evaluated in Phase II clinical trials. GCC is a marker expressed in several gastrointestinal cancers, and Liminatus is studying whether an immune-based approach can help target malignancies such as colorectal, pancreatic, gastric, and oesophageal cancers. These are large oncology indications where improved treatment options are still needed, particularly for patients whose disease is advanced or resistant to standard care.
Liminatus is also developing a next-generation CD47 immune checkpoint inhibitor. CD47 is often described as a “don’t eat me” signal used by cancer cells to avoid clearance by the immune system. Blocking this pathway is a recognised strategy in cancer immunotherapy, but some anti-CD47 antibodies can bind to red blood cells and platelets, raising safety concerns such as anaemia, thrombocytopenia, and haemolysis. Liminatus says its CD47 monoclonal antibody is designed to bind preferentially to immune cells rather than red blood cells or platelets, with the aim of improving tolerability. This candidate is in late preclinical development, meaning it has not yet reached human efficacy testing.
Last updated
- Market Cap
- $7,501,812
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- —
- Sector
- Materials
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 12611 HIDDENCREEK WAY, CERRITOS, CA, 90703
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Liminatus Pharma Amends Merger Agreement With InnocsAI To Expand Oncology Pipeline
Liminatus Pharma secures $1.9M cash via warrant exercises
Liminatus Pharma Announces Nasdaq Delisting Notification
Form 8K Liminatus Pharma Inc For: 25 August
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $7,501,812
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- —
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- —
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- —
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- —
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- —
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- —
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- —
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- —
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- —
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- —
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- —
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- —
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- —
Financial statements are not available for this listing.
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Liminatus Pharma, Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 4 — Liminatus Pharma, Inc. | View Filing | |
| edgar index | DEF 14A — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 3 — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 4 — Liminatus Pharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 3 | Form 3 — Ewon Comfortech Co., Ltd. | View Filing | |
| form 4 | Form 4 — Kim Chris | View Filing | |
| form 4 | Form 4 — Valetudo Therapeutics LLC | View Filing | |
| form 4 | Form 4 — Valetudo Therapeutics LLC | View Filing | |
| form 4 | Form 4 — Kim Chris | View Filing | |
| edgar index | PRE 14A — Liminatus Pharma, Inc. | View Filing | |
| edgar index | S-1 — Liminatus Pharma, Inc. | View Filing | |
| form 4 | Form 4 — Valetudo Therapeutics LLC | View Filing | |
| form 4 | Form 4 — Kim Chris | View Filing | |
| edgar index | D — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 424B3 — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 10-K — Liminatus Pharma, Inc. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 424B4 — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | EFFECT — Liminatus Pharma, Inc. | View Filing | |
| edgar index | S-1 — Liminatus Pharma, Inc. | View Filing | |
| edgar index | CORRESP — Liminatus Pharma, Inc. | View Filing | |
| edgar index | CORRESP — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| edgar index | UPLOAD — Liminatus Pharma, Inc. | View Filing | |
| edgar index | DRS — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 10-Q — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 10-Q — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| edgar index | NT 10-Q — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 3 — Liminatus Pharma, Inc. | View Filing | |
| form 3 | Form 3 — Iris Acquisition Holdings LLC | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 424B3 — Liminatus Pharma, Inc. | View Filing | |
| edgar index | EFFECT — Liminatus Pharma, Inc. | View Filing | |
| edgar index | CORRESP — Liminatus Pharma, Inc. | View Filing | |
| edgar index | S-1/A — Liminatus Pharma, Inc. | View Filing | |
| edgar index | CORRESP — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 3 — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 3 — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| edgar index | UPLOAD — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 8-K — Liminatus Pharma, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Liminatus Pharma, Inc. | View Filing | |
| edgar index | 3 — Liminatus Pharma, Inc. | View Filing |